Comorbidities of pediatric systemic lupus erythematosus: A 6-year nationwide population-based study.

OBJECTIVE Systemic lupus erythematous (SLE) is a systemic and complex disease that can involve multiple organs. To clarify the risk of developing associated comorbidities after a diagnosis of SLE in children, we used the National Health Insurance Research Database (NHIRD) in Taiwan to investigate diseases experienced in these patients. This is the first nationwide population-based study of the comorbidities of pediatric SLE patients. METHODS The study was based on data from the NHIRD in Taiwan. Children were enrolled who were below the age of 18 years and whose disease corresponded to the International Classification of Disease, Ninth Revision Clinical Modification (ICD-9-CM) diagnostic code of 710.0 (SLE). The comorbidities associated with SLE were defined by the ICD-9-CM codes of diseases that presented after the SLE diagnosis. We analyzed the common diseases in SLE patients and compared the frequency of these diseases between pediatric SLE patients and the non-SLE population. RESULTS From January 1, 2003 to December 31, 2008, we enrolled 904 SLE patients (774 females, 130 males). Infection (86.36%) was the most common comorbidity in pediatric SLE. Other comorbidities were musculoskeletal diseases (16.7%), cardiovascular diseases (16.37%), ocular diseases (10.73%), and renal diseases (6.75%). Children with SLE had a higher risk of heart failure, hypertension, osteoporosis, cataracts, glaucoma, dyslipidemia, seizures, encephalopathy, and malignant changes, compared to non-SLE populations. CONCLUSION The population-based cohort demonstrated several systemic and/or chronic diseases in pediatric SLE patients in Taiwan. Children with SLE were more susceptible to these diseases, including malignancy, compared to the non-SLE population.

[1]  C. Gordon,et al.  Lupus and cancer , 2009, Lupus.

[2]  A. Reiff,et al.  Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. , 2003, Arthritis and rheumatism.

[3]  C. Gasparini,et al.  Relationship between Damage Accrual, Disease Flares and Cumulative Drug Therapies in Juvenile-Onset Systemic Lupus Erythematosus , 2006, Lupus.

[4]  D. Gladman,et al.  Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus , 2001, Lupus.

[5]  A. Martini,et al.  A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[6]  J. Beyene,et al.  Rheumatic Disease and Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[7]  J.-L. Huang,et al.  Pediatric lupus in Asia , 2010, Lupus.

[8]  J. Reveille,et al.  Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. , 1993, Arthritis and rheumatism.

[9]  H. Brunner,et al.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? , 2010, Rheumatic diseases clinics of North America.

[10]  A. Voss,et al.  SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study , 2010, Lupus.

[11]  Yao-Hsu Yang,et al.  Retrospective analysis of the renal outcome of pediatric lupus nephritis , 2004, Clinical Rheumatology.

[12]  L. Hiraki,et al.  Review: Measuring permanent damage in pediatric systemic lupus erythematosus , 2007 .

[13]  A. Voss,et al.  Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort. , 1998, Scandinavian journal of rheumatology.

[14]  L. Vilá,et al.  Prevalence of Systemic Lupus Erythematosus and Associated Comorbidities in Puerto Rico , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[15]  B. Tom,et al.  Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus , 2008, The Journal of Rheumatology.

[16]  G. Hughes,et al.  Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients , 2003, Medicine.

[17]  C. Gordon,et al.  Assessment of lupus: where are we now? , 1993, Annals of the rheumatic diseases.

[18]  M. Urowitz,et al.  The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study , 2007, Annals of the rheumatic diseases.

[19]  J. Esdaile,et al.  Systemic lupus erythematosus in North American Indians: a population based study. , 2000, The Journal of rheumatology.

[20]  Chiu Ym,et al.  Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. , 2010 .

[21]  M. Ognjanović,et al.  Lupus nephritis in childhood: a review of 53 patients followed at a single center , 2003, Pediatric Nephrology.

[22]  A. Ekbom,et al.  A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study , 2007, Annals of the rheumatic diseases.

[23]  Y. Chiu,et al.  Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. , 2010, Lupus.

[24]  Yao-Hsu Yang,et al.  Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. , 2003, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[25]  E. Yow,et al.  Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. , 2009, Arthritis and rheumatism.

[26]  A. Smit,et al.  Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. , 2009, Atherosclerosis.

[27]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[28]  Javier Martín,et al.  Metabolic Syndrome Is Associated with Increased Arterial Stiffness and Biomarkers of Subclinical Atherosclerosis in Patients with Systemic Lupus Erythematosus , 2009, The Journal of Rheumatology.

[29]  L. Kovács,et al.  Malignancies in systemic lupus erythematosus. , 2010, Autoimmunity reviews.

[30]  F. Granath,et al.  Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. , 2004, The Journal of rheumatology.

[31]  M. Lauer,et al.  Mortality outcomes in pediatric rheumatology in the US. , 2010, Arthritis and rheumatism.

[32]  D. Gladman,et al.  The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[33]  J. L. Huang,et al.  The morbidity and mortality associated with childhood onset systemic lupus erythematosus. , 1994, Changgeng yi xue za zhi.

[34]  C. Bombardier,et al.  Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. , 2002, Arthritis and rheumatism.

[35]  A. Reiff,et al.  Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. , 2004, Arthritis and rheumatism.

[36]  A. Martini,et al.  Outcome in juvenile onset systemic lupus erythematosus , 2005, Current opinion in rheumatology.